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Abstract
Two previous pan-European consensus meetings, the 1995 and 2006 Helsingborg meetings, were convened to review
the scientific evidence and the state of current services to identify priorities for research and development and to set
targets for the development of stroke care for the decade to follow. Adhering to the same format, the European Stroke
Organisation (ESO) prepared a European Stroke Action Plan (ESAP) for the years 2018 to 2030, in cooperation with the
Stroke Alliance for Europe (SAFE). The ESAP included seven domains: primary prevention, organisation of stroke
services, management of acute stroke, secondary prevention, rehabilitation, evaluation of stroke outcome and quality
assessment and life after stroke. Research priorities for translational stroke research were also identified. Documents
were prepared by a working group and were open to public comments. The final document was prepared after a
workshop in Munich on 21–23 March 2018. Four overarching targets for 2030 were identified: (1) to reduce the
absolute number of strokes in Europe by 10%, (2) to treat 90% or more of all patients with stroke in Europe in a
dedicated stroke unit as the first level of care, (3) to have national plans for stroke encompassing the entire chain of care,
(4) to fully implement national strategies for multisector public health interventions. Overall, 30 targets and 72 research
priorities were identified for the seven domains. The ESAP provides a basic road map and sets targets for the imple-
mentation of evidence-based preventive actions and stroke services to 2030.
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Introduction
Stroke remains one of the leading causes of death and
disability in Europe, and projections show that with a
‘business as usual’ approach, the burden of stroke will
not decrease in the next decade or beyond. An impor-
tant contributing factor to this is that the number of
older persons in Europe is rising, with a projected
increase of 35% between 2017 and 2050.1
Fortunately, there is compelling evidence that stroke
is highly preventable, treatable and manageable, and
the potential exists to drastically reduce the burden of
stroke and its long-term consequences. However, this
requires the joint actions of ministries of health, other
governmental bodies, scientific and stroke support
organisations, healthcare professionals, clinical and
preclinical researchers and the pharmaceutical and
device industries.
To this end, two previous pan-European consensus
meetings, the 1995 and 2006 Helsingborg meetings,2,3
were convened to review the scientific evidence and the
state of current services and to set targets for the devel-
opment of stroke care for the decade to follow. The
European Stroke Organisation (ESO) has prepared a
European Stroke Action Plan (ESAP) for the years
2018 to 2030, in cooperation with the Stroke Alliance
for Europe (SAFE). The ESAP adheres to the format
of the Helsingborg Declarations, presenting a review of
the ‘state of the art’, the state of current services,
research and development priorities and targets for a
series of domains in stroke care (organisation of stroke
services, management of acute stroke, prevention, reha-
bilitation, evaluation of stroke outcome and quality
assessment). The ESAP includes two additional
domains, on primary prevention and life after stroke,
along with research and development priorities for
translational stroke research. ESAP 2018–2030
complements the WHO Global Action Plan on non-
communicable diseases (NCDs) 2013–2020, the
WHO-Europe NCD Action Plan and the UN
Sustainable Development Goals for 2015 to 2030.
Overarching targets for 2030
For each domain of the 2018 to 2030 ESAP, specific
targets are being set, as detailed in the following
sections. Beyond these targets, four overarching targets
for 2030 have been identified:
1. to reduce the absolute number of strokes in Europe
by 10%
2. to treat 90% or more of all patients with stroke in
Europe in a dedicated stroke unit as the first level
of care
3. to have national plans for stroke encompassing the
entire chain of care from primary prevention to life
after stroke.
4. to fully implement national strategies for multisector
public health interventions to promote and facilitate
a healthy lifestyle, and reduce environmental
(including air pollution), socioeconomic and educa-
tional factors that increase the risk of stroke.
Methods
The work was led by a steering committee. The docu-
ments were prepared by working groups for each of the
seven domains, with patient organisation representa-
tives in each domain. Research priorities were identi-
fied by two persons for each domain. One working
group prepared research priorities for translational
stroke research. The draft documents were open to
public comments during a one-month period. The
final document was prepared after a workshop in
Munich on 21–23 March 2018 that was streamed live.
Primary prevention
State of the art
Primary prevention of stroke is part of both primary
healthcare and public health. Stroke prevention, which
involves both pharmacological and non-
pharmacological interventions, targets many of the
same risk factors as those involved in other cardiovas-
cular diseases (CVDs) and other NCDs. Thus, primary
prevention of stroke has two integral components,
which can be implemented at different levels. First,
measures to promote a healthy lifestyle, such as smok-
ing cessation and reducing alcohol intake, can be
implemented at the individual patient level. Second,
reductions in air pollution and improvements in
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socioeconomic and educational status require action at
governmental and societal level.
Risk factor modification. Ten modifiable risk factors may
account for the vast majority of the population attrib-
utable risk of stroke, across age groups, genders and
ethnicity. These risk factors are: hypertension, smok-
ing, dyslipidaemia, unhealthy diet, physical inactivity,
obesity, diabetes mellitus, cardiac disease, excessive
alcohol intake and psychosocial factors.4 There is over-
whelming evidence that the treatment of cardiovascular
risk factors reduces the risk of stroke, but the target
levels in primary prevention are less stringent than
those in secondary prevention and depend on comor-
bidities such as diabetes mellitus and active smoking;
these targets may differ between men and women.5
There is good evidence to support risk factor modifica-
tion as primary prevention in individuals aged 40–75
years, but the optimal target levels for the management
of hypertension and dyslipidaemia in persons outside
this age range are less well established.5,6
Hypertension, diabetes mellitus, dyslipidaemia,
smoking, unhealthy diet, obesity, physical inactivity
and atrial fibrillation (AF) are the strongest and most
common modifiable risk factors for stroke,7,8 and most
guidelines include these risk factors. Based on an exten-
sive literature, most primary prevention guidelines rec-
ommend the use of risk tables, which take age and
comorbidities into account. In a European setting,
the Systematic COronary Risk Evaluation (SCORE)
tables, accessible through the European Society of
Cardiology website, are appropriate, since they are
derived from a mixed European population. An
adapted version for older people, SCORE-OP,
is available.9
Self-management, with or without the use of tech-
nology such as eHealth and mobile health (mHealth)
initiatives, may offer the possibility of delivering pri-
mary prevention in a range of healthcare settings,
including geographically remote areas in Europe.
However, the expected impact on risk factor improve-
ment is modest at best, and sustainability of effects is a
major challenge.10 A consistent and constructive col-
laboration between healthcare professionals in prima-
ry, secondary and tertiary care is likely to be essential
for sustainable primary prevention.
Primary prevention in public health. Primary prevention
can be delivered at the individual, community and pop-
ulation levels. Public health interventions targeting
highly prevalent risk factors that do not require phar-
macological intervention, including discouraging
smoking and encouraging a healthy lifestyle, should
be implemented at several levels; such interventions
may include legislative changes, media campaigns,
labelling of food and educational and preventive meas-
ures in schools, workplaces and the community.
Although there is only limited high-quality evidence
for a direct effect on the incidence of stroke and
CVD, initiatives such as building cycle lanes, guiding
people to stairs, serving healthy food in public places,
smoking bans, decreasing the amount of salt and sugar
in processed food and soft drinks, health education and
public health campaigns to increase awareness of mod-
ifiable stroke risk factors are sensible public health
interventions and should be pursued.
From a population perspective, it is not sufficient to
target only those individuals at high risk of CVD. The
majority of strokes will develop in persons with low or
intermediate risk,11 and hence broad prevention strat-
egies targeting the wider population are indicated, par-
ticularly considering the high prevalence of some of the
strongest risk factors for stroke. A combination of
opportunistic screening of those at increased risk
(based, for example, on demographic characteristics)
and systematic screening for risk factors is probably
most appropriate.5 In particular, raising awareness of
hypertension as a risk factor for stroke could increase
early detection rates and lead to earlier initiation of
treatment. Many risk factors are more prevalent
among people with low socioeconomic status, and
extra effort to reach these people with preventive strat-
egies is warranted.12 In all situations, the potential ben-
efits and risks – such as over-medicalisation – should be
carefully evaluated.
State of current services
There are major differences among European coun-
tries, indirectly reflecting the state of local services, in
terms of risk factor prevalence and control.7 Moreover,
awareness of the modifiable risk factors for stroke can
vary markedly between populations.8 The organisation
of primary prevention services differs greatly between
European countries. Some countries, such as the
Netherlands and the United Kingdom, have a strong
primary care system, and extensive guidelines that
include the primary prevention of CVD are in place,
whereas in other countries, it is less clear who is prin-
cipally responsible for primary prevention. There are
currently no generally accepted European guidelines as
to which populations should be screened, for which risk
factors and at which age. A national NCD action plan
is a prerequisite for successful primary prevention strat-
egies that are feasible and realistic for each country, but
not all European countries have such a plan.12
Blood pressure management. The prevalence of hyperten-
sion in people above the age of 18 years ranges from 20
to 40% in Europe.8 Of those on medical treatment,
Norrving et al. 3
only a minority sustainably reach their target
blood pressure.13
Smoking. A steady decline in smoking since 1990 has
occurred among men and women in most European
countries. However, 10–28% of the adult populations
in European countries still smoke.14,15
Obesity, diet and physical activity. The prevalence of over-
weight and obesity has increased dramatically over the
last 25 years. National programmes to reduce salt con-
sumption have been successful in many European
countries, with high evidence of a beneficial effect on
cardiovascular mortality in some countries.
Furthermore, 6 out of 10 European citizens do not
reach the WHO-recommended 150min of moderate
intensity physical activity per week.7
Dyslipidaemia. The number of people with untreated
dyslipidaemia has decreased over the last 25 years,
but adherence to treatment with cholesterol-lowering
drugs is still poor, with less than half of patients
being sustainably adherent to their medication.16
Diabetes mellitus. Diabetes care can be organised in out-
patient clinics or in primary care, coordinated by spe-
cialised nurses. The percentage of patients with
adequate diabetes control can be estimated based on
the glycated haemoglobin (HbA1C) level and varies
between European countries, reflecting different levels
of service.
Atrial fibrillation. AF-related stroke is increasing in inci-
dence and prevalence: this may be related to better
detection but is at least partly the result of the increas-
ing incidence of AF with age and the ageing population
in most countries. In people with AF with an appro-
priate CHA2DS2VASc score, the beneficial effect of
anticoagulation is evident, but the value of wider
screening for AF and the clinical significance of short
episodes of paroxysmal AF are currently under debate,
particularly if it concerns primary prevention. The bal-
ance between benefits and harms of long-term antico-
agulation as primary prevention is questionable in
some AF patients, particularly those with very short
episodes of AF or a low CHA2DS2VASc score.
17
Because stroke and CVDs share many common risk
factors, research initiatives in primary prevention of
stroke should not be undertaken in isolation. Close
collaboration with primary prevention initiatives from
cardiology, primary healthcare and public health is
strongly recommended and should be covered by a
regional or national NCD action plan. Such initiatives
should be aligned with WHO initiatives such as the
Action Plan for NCD, and updated as necessary
when these are revised.
Research and development priorities
1. Which factors are responsible for major health dis-
parities in Europe, including risk factor prevalence
and control, and access and adherence to primary
prevention? What are the effects of low socioeco-
nomic status and other social factors?
2. Can the current risk prediction models be improved
by extending the current 10-year risk prediction to
20-year or life-time risk for those at younger age
(<40 years), and five-year or life-time risk for
those over 75 years?
3. Can further individualisation of primary prevention
strategies, for example, by considering multiple
comorbidities, poly-pharmacy, geographic and
ethnic differences and polygenetic risk profiles,
enhance effectiveness?
4. Can public awareness of the potential for primary
prevention of stroke be improved by personalised
and public health education about modifiable
risk factors?
5. What are the benefits and harms of screening for
stroke risk factors in different populations, using
different approaches such as systematic and oppor-
tunistic screening?
6. Can adherence to primary prevention interventions
be improved by using eHealth or mHealth
approaches to encourage self-management, using
drug combinations (for example, in ‘polypill’ formu-
lations), and combining individualised approaches
with public health interventions?
Targets for 2030
1. Achieving universal access in Europe to primary
preventive treatments based on improved and
more personalised risk prediction.
2. Full implementation of national strategies for multi-
sectorial public health interventions promoting and
facilitating a healthy lifestyle, and reducing environ-
mental, socioeconomic and educational factors that
increase the risk of stroke.
3. Making available evidence-based screening and
treatment programmes for stroke risk factors in all
European countries.
4. Having blood pressure detected and controlled in
80% of persons with hypertension.
As with the research and development priorities, close
collaboration and alignment with cardiovascular dis-
ease prevention targets are essential to meet these pro-
posed targets.
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Organisation of stroke services
State of the art
The organisation of stroke services is fundamental to
quality care across the spectrum of care that progresses
from prevention via acute therapy to long-term care.
Definitions of the different facilities for stroke care
included into this document are provided in Table 1.
The focus of this section is on the organisation of acute
stroke treatment services, since other elements will be
presented in the sections dealing with specific domains.
Although organised services exist in most European
countries, there is large variability in the practical
application of treatment guidelines and adherence to
quality indicators.19 Awareness programmes have
been shown to have an impact on the number of
acute stroke calls, but this effect is not sustained in
the long term.20 National or regional quality registries
have been implemented in several countries to monitor
key performance indicators, and programmes to certify
stroke units and stroke centres have been established in
others.21 Research activities, covering both experimen-
tal and clinical studies, and funding have significantly
increased during the last decades.22
Appropriate training of emergency medical services
(EMS) personnel and dispatchers increases the number
of patients arriving early at hospital, and several coun-
tries have established clear transportation routes to the
closest suitable hospital.23 Pre-hospital identification of
patients with acute stroke by use of validated tools and
scales has been recognised as being important for
prompt treatment: the Face Arm Speech Test (FAST)
is the easiest and the most commonly used, but all pre-
hospital scales demonstrate suboptimal specificity, even
with adequate training.24,25 The development of stroke
teams (including all disciplines required for acute
stroke management including radiology) has been
shown to lead to shorter delays and more rapid man-
agement, particularly when the team is pre-notified of
the imminent arrival of the patient.26,27 The concept of
delivering personnel and equipment to the patient via
mobile stroke units seems to be effective, but this
option is not widely available.28 The same is true for
helicopter transportation, which may be useful in cer-
tain settings.29
Admission to centralised, rather than non-
centralised, facilities for acute hospital care increases
the likelihood of receiving thrombolytic treatment,
which has a direct impact on stroke outcome.30
Hospitals with greater use of thrombolysis achieve sta-
tistically and clinically significantly shorter delays in
administering tissue plasminogen activator (tPA) after
arrival in hospital.31 This may be also true for mechan-
ical thrombectomy, but data on this are limited at
present. Treatment in dedicated stroke units signifi-
cantly reduces the risk of disability, institutional care
and death by 20%, irrespective of stroke severity and
age.32 All hospitals should ensure that patients with
suspected stroke have rapid access to brain imaging,
including vascular imaging at all times, since immediate
brain imaging is the most cost-effective approach in
stroke.33 Early supported discharge (ESD) in a multi-
disciplinary setting is beneficial for patients with mild
to moderate stroke and is a likely cause of the signifi-
cant reduction in length of stay in stroke units in these
patients.34,35
In remote regions without specialist stroke expertise,
telemedicine in community hospitals may help to pro-
vide evidence-based acute stroke treatment, including
thrombolysis.36 Certification and sentinel stroke audit
programmes support the delivery of high-quality
organised care: it has been shown that high perfor-
mance in audited process indicators reduces mortality
by up to 25%.37 This emphasises the need for
Table 1. Definitions of selected terms used in the European
Stroke Action Plan.
Stroke unit: A dedicated geographically clearly defined area or
ward in a hospital, where stroke patients are admitted and
cared for by a multi-professional team (medical, nursing and
therapy staff) who have specialist knowledge of cerebral
function, training and skills in stroke care with well-defined
individual tasks, regular interaction with other disciplines and
stroke leadership. This team coordinates care through regular,
multidisciplinary meetings.18
Stroke centre: A hospital infrastructure and related processes
of care that provide the full pathway of stroke unit care. A
stroke centre is the coordinating body of the entire chain of
care. This covers pre-hospital care, ongoing rehabilitation and
secondary prevention and access to neurosurgical and vascular
intervention. A stroke unit is the most important component
of a stroke centre. The Stroke Centre provides stroke unit
services for the population of its own catchment area and
serves as a referral centre for peripheral hospitals with stroke
units in case their patients need services which are not avail-
able locally.18
Comprehensive stroke unit: A dedicated area where acute
stroke management is combined with early mobilisation and
rehabilitation and secondary prevention, according to the
needs of the patient.
Early supported discharge: Early supported discharge is
designed to enable the accelerated discharge of stroke patients
to their home, providing specialist rehabilitation and social
support in a home setting rather than an acute hospital ward.
The early supported discharge team comprises a variety of
specialist therapists, social and support workers. The team
visits patients in their home setting, enabling patients to
undergo rehab in a familiar home setting, and thus increasing
patient flow and bed availability within the acute hospital.
Registry: A system for collecting process and outcome data at
regional or national level that achieves near universal coverage.
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continuing quality improvement processes, particularly
in view of the known differences in care quality related
to time and day of admission.38 Auditing measures lead
to a better quality of stroke care, and more sustained
stroke care performance over time.39
State of current services
Political awareness of the burden of stroke has
increased in recent years, but still varies significantly
across Europe. Although significant progress has been
made, there is still large heterogeneity in the organisa-
tion of stroke care in Europe, as shown by a recent
ESO survey in 44 countries.40 Hence, reliable and pre-
cise information about the structure and organisation
of stroke care, and the implementation of stroke man-
agement pathways, is still lacking in many countries. In
most, but not all, European countries, health services
and political structures are linked to a national stroke
society, and these linkages help to coordinate
stroke services and foster quality improvements of
stroke care. Most countries have an EMS system with
regional organisation and written protocols for acute
stroke. However, many do not have obligatory trans-
port routes to the closest suitable hospital or proce-
dures for pre-hospital notification of hyper-acute
stroke. Although stroke symptoms and the importance
of immediate action have repeatedly been communicat-
ed to the public, awareness is still unsatisfactory among
the general population.
The crucial impact of time in acute stroke has con-
stantly been stressed, but fewer than 10% of stroke
patients reach the hospital within 60min of symptom
onset. In many countries, the symptom-to-hospital
delay has not decreased in recent years. Several coun-
tries have built a nationwide network of hospitals with
stroke units or stroke centres following written proto-
cols. However, only limited information on the defini-
tions of stroke units and comprehensive stroke centres
in the various countries is available. Moreover, only a
minority of countries have established a certification
system with well-defined quality criteria, or a moni-
tored system for benchmarking delivery of care, that
is evaluated at regular intervals. Among the options for
acute stroke care, mechanical thrombectomy is the
latest and the most challenging component, and there
is currently huge variation in the delivery of this treat-
ment across Europe.40
Only a few countries have established a continuous
quality improvement system with a predefined set of
criteria that are regularly measured and compared
with benchmarks. The reimbursement structures for
stroke care are still highly variable between European
countries, leading to gaps in care quality in some coun-
tries. The challenges for acute stroke care differ
markedly between countries, and between different
regions (e.g. cities, rural areas), but only a few coun-
tries monitor the delivery of stroke care at a patient
level to ensure a defined standard of service.
Research and development priorities
1. Can we identify the most relevant barriers to the
implementation of evidence-based stroke care?
What is the role of economical aspects?
2. What is the health-economic impact of strokes and
the return of investment in stroke care?
3. Which are the most cost-effective concepts to
improve the organisation of stroke care in coun-
tries with limited resources?
4. Which are the minimum educational criteria for
stroke experts (physicians, nurses or therapists)?
5. What are the optimum numbers and ratios of
stroke centres and stroke units for municipal and
rural areas?
6. What is the role of telemedicine systems for acute
stroke, rehabilitation and long-term care?
7. What is the appropriate structure to manage child-
hood stroke?
8. How can regional networks of EMS, stroke units
and rehabilitation centres be developed most
effectively?
9. How can evidence-based media campaigns be
organised in order to promote public awareness
and knowledge of stroke signs and the importance
of immediate action?
10. What elements are needed to enable more effective
participation in decision making among patients
and relatives?
Targets for 2030
1. Establishing a medical society and stroke support
organisation in each country, which collaborates
closely with the responsible body in developing,
implementing and auditing the national stroke plan.
2. Guiding national stroke care by evidence-based
pathways that cover the entire chain of care. These
pathways are understood by the public and may be
adapted to meet regional circumstances to ensure
equal access to stroke care irrespective of patient
characteristics, region and time of hospitalisation.
3. Managing and delivering stroke care by competent
personnel and teams, and creating plans for effective
recruitment and training as part of a national
stroke plan.
4. All stroke units and other stroke services undergo
regular certifications or equivalent auditing pro-
cesses for quality improvement.
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Management of acute stroke
State of the art
Acute stroke is a medical emergency. The benefit of
recanalisation therapies in patients with acute ischae-
mic stroke is strongly time-dependent, with earlier
intervention achieving better outcomes.41 Stroke care
systems should therefore minimise the time to assess-
ment and initiation of treatment, before brain injury
becomes irreversible.42,43 All patients with ischaemic
stroke or intracranial haemorrhage (ICH) benefit
from specialist attention and organised care within a
designated stroke unit (number needed to treat (NNT)
to prevent poor outcome, 18) including rapid diagnos-
tic imaging, probably due in part to the prevention or
early treatment of complications such as infections and
fever.32 Randomised trials testing strategies to prevent
complications are ongoing.32,44
For ischaemic stroke, aspirin – started within two
days of the onset of symptoms – has a small benefit
(NNT 79) but is suitable for a large number of patients.
Although unproven, the benefit of early treatment with
clopidogrel is probably comparable. In selected
patients with acute ischaemic stroke or TIA, dual anti-
platelet therapy in the first weeks confers additional
benefit.45 Selected interventions, including intravenous
thrombolysis, endovascular thrombectomy (EVT) and
hemicraniectomy, offer greater benefit but are applica-
ble to fewer patients than antiplatelet therapy. Timely
restoration of blood flow through intravenous throm-
bolysis (IVT, NNT 5–9) or EVT (NNT 3) is the first
priority. The earlier the treatment with IVT is initiated,
the greater the benefit, irrespective of age or stroke
severity.42 In patients with acute ischaemic stroke
caused by occlusion of a proximal intracranial artery
of the anterior circulation, EVT strongly increases the
chance of a good outcome and, like alteplase, improves
global functional outcomes. The initial evidence of ben-
efit with EVT was largely limited to patients in whom
treatment could be started within 6 h of symptom
onset, but recent evidence suggests that, in highly
selected patients with acute ischaemic stroke and con-
siderable residual mismatch between perfusion deficit
and infarct volume, EVT can offer benefit when used
up to 24 h of symptom onset. In recent trials, EVT was
associated with a 19% absolute reduction in the risk of
a poor outcome, but nevertheless 29–67% of the
patients randomised to the intervention arm were
dead or dependent at three months.46–50
The wake up study reported that in selected patients
with acute stroke with an unknown time of onset, intra-
venous alteplase guided by a mismatch between
diffusion-weighted imaging (DWI) and fluid-attenuated
inversion recovery (FLAIR) in the region of ischemia
is beneficial.51
For patients aged 60 years or younger with large,
space-occupying infarctions, surgical decompression
involving hemicraniectomy and duraplasty strongly
reduces the risk of death or dependency (NNT 2–4).52
The benefit in older patients is questionable because
surgical decompression in the elderly reduces the risk
of death at the cost of a large increase in the risk of
long-term dependency in activities of daily living
(ADL).53 For patients with ICH, care on a stroke
unit is the only treatment that has been demonstrated
to be beneficial. Early intensive blood pressure lower-
ing may improve outcome, although the NNT is rela-
tively large.54 To date, the use of haemostatic agents to
prevent early haematoma growth has not been proven
effective. Surgical treatment may be life-saving in some
patients, but a surgical intervention policy has not been
shown to improve outcome in patients with ICH in
general.55,56
In patients with subarachnoid haemorrhage (SAH)
caused by a rupture of an intracranial aneurysm, the
primary goal is the prevention and treatment of com-
plications such as rebleeding, delayed cerebral ischae-
mia and hydrocephalus. The risk of rebleeding can be
reduced by occlusion of the aneurysm with endovascu-
lar or microneurosurgical techniques; coiling is pre-
ferred in cases where both treatment options appear
equally feasible. Oral nimodipine reduces the risk of
delayed cerebral ischaemia and increases the chance
of a favourable outcome.57,58 Early, short-term, treat-
ment with tranexamic acid to reduce the risk of recur-
rent SAH before the aneurysm is secured, is currently
under study.
Many in-hospital deaths of stroke patients occur
after a decision to withhold or withdraw life-
sustaining treatments. Observational studies have
demonstrated a strong relation between treatment
restrictions, such as do-not-resuscitate orders and an
increased risk of in-hospital mortality. It remains
uncertain whether this relation is causal, and whether
refraining from do-not-resuscitate orders would result
in better outcomes.59
State of current services
A recent survey of access to, and delivery rates of, acute
stroke unit care, IVT and EVT in 44 European coun-
tries found major inequalities in acute stroke treatment
between and within countries.40 Overall, there were 1.5
stroke units per 1000 annual incident ischaemic strokes,
but individual country-level data indicate that both
access to and delivery of acute stroke care are insuffi-
cient or lacking in many countries. Furthermore,
regional differences were reported within 28 countries.
Norrving et al. 7
Fewer than 20% of patients with acute ischaemic
stroke had access to treatment with IVT, and the over-
all rate of IVT in incident ischaemic stroke was 7.3%,
with considerable inter- and intra-country variability.
EVT was performed in only 0.4 centres per 1000 annual
incident ischaemic strokes, and only 1.9% of all acute
ischaemic stroke patients were estimated to have
received this treatment. Moreover, 28 countries
lacked full EVT coverage.40
The mainly Western European SITS-MOST registry
has reported a median onset-to-treatment time of
140min, compared with 150min reported by the
Eastern European SITS-EAST registry. A median
door-to-needle (DNT) time of 70min has been
reported in international European registries; continu-
ous improvement of processes can limit median DNT
times to just 20min in experienced and high-
volume centres.
Guidelines for the management of ICH generally
recommend early blood pressure control in patients
with acute ICH. Unfortunately, European data on
the use of antihypertensive treatment in this setting,
and the degree of blood pressure control achieved,
are scarce.
Research and development priorities
1. How can disparities in access to stroke unit care
across European countries be diminished?
2. Which reperfusion options should be used, based on
patient-, service- and cost-specific factors?
3. How can the speed, safety and effectiveness of reper-
fusion approaches (drugs or devices) be optimised
in Europe?
4. Which pharmacological or other strategies will
reduce the extent of irreversible brain damage in
ischaemic stroke patients before recanalisation ther-
apies are started?
5. Which strategies will improve outcomes in ischaemic
stroke patients who are not eligible for reperfusion
therapies, or who do not recover after
recanalisation?
6. Which treatment strategies will improve outcomes in
patients with ICH: haemostatic and surgical
approaches, prevention of secondary injury, or
intensive and tailored blood pressure management?
7. Which treatment strategies will further improve out-
comes in patients with SAH by reducing
brain injury?
Targets for 2030
1. Treating 90% or more of all patients with stroke in
Europe in a stroke unit as the first level of care.
2. Guaranteeing access to recanalisation therapies to
95% of eligible patients across Europe.
3. Decreasing median onset-to-needle times to
<120min for intravenous thrombolysis and onset-
to-reperfusion times to <200min for endovascu-
lar treatment.
4. Achieving IVT rates above 15%, and EVT rates
above 5%, in all European countries.
5. Decreasing first-month case-fatality rates to <25%
for ICH, and increasing the rate of good functional
outcomes to >50%.
6. Decreasing first-month case-fatality rates to <25%
for SAH, and increasing the rate of good functional
outcomes to >50%.
Secondary prevention
State of the art
In the Helsingborg Declaration of 2006,3 the goals for
2015 were to reduce stroke mortality by at least 20%,
and for all patients with TIA or stroke to receive
appropriate secondary preventive measures. Within
Europe, all countries agree that stroke risk factors,
most importantly hypertension and smoking, should
be reduced in their populations, but implementation
of secondary prevention measures varies considerably
between countries, with declining success rates from
west to east.
Secondary prevention encompasses the reduction of
further stroke and TIA, any other vascular disease, and
other complications including cognitive decline
and dementia, mood disturbances or anxiety, fatigue
and poor quality of life. Secondary prevention applies
to almost all patients with stroke or TIA and can reduce
stroke recurrence by 80%. Investigation and treatment
must commence in hospital (stroke unit or stroke clinic)
and continue throughout life in the community.
Applicable ESO and national guidelines are regularly
updated, and most investigations and interventions are
available to healthcare systems across Europe. The rou-
tine use of these guidelines will ensure equity of access
and equality of care across Europe.
Investigations. Investigations of incident stroke, and its
cause(s) and risk factors, should follow guideline-based
local protocols including rapid and appropriate brain
and vascular imaging (Table 2); recurrent strokes
should be re-investigated since the mechanism may be
different from that of the original stroke. If magnetic
resonance imaging (MRI) is performed, it should
include T2, FLAIR, DWI and blood-sensitive sequen-
ces. If there is no obvious cause of stroke, identifying
paroxysmal AF and patent foramen ovale (PFO)
become important.
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The identification of risk factors has two major cor-
nerstones: identifying ‘lifestyle’ risk factors that would
benefit from a personalised approach and ‘medical’ risk
factors for which management guidelines exist.
Modifiable risk factors such as poor diet, alcohol and
tobacco use, drug addiction, obesity, high blood pres-
sure and cholesterol, AF, diabetes mellitus and sleep
apnoea, must be addressed in every patient (Table 3).
Non-modifiable factors, such as age, sex, race or eth-
nicity and family history, modulate the importance of
modifiable factors: national stroke registers should
record the presence of these factors, and interventions
used to prevent or treat modifiable risk factors.
The minimum standard of care for secondary pre-
vention consists of lifestyle advice and lowering elevat-
ed blood pressure; in patients with ischaemic events,
antithrombotic therapy, a statin and carotid endarter-
ectomy (if appropriate) should be added. Patient and
carer education about prevention strategies60 should be
delivered at every opportunity by all healthcare profes-
sionals working in stroke care. Interventions should be
started in hospital, with targets that are defined by a
multidisciplinary panel and reviewed on a regular basis.
The effect of treatment on blood pressure and lipids
should be assessed at follow-up.
Following the diagnosis of ischaemic stroke or TIA,
the aetiological cause (large artery disease, cardioemb-
olism, small vessel disease (SVD), stroke of other deter-
mined aetiology and stroke of undetermined aetiology)
should be identified. This approach allows treatment
with appropriate secondary preventative strategies
(Table 3); this summary of interventions will be
updated in future ESO and other guidelines. A similar
approach should be taken for the diagnosis of ICH,
which may be lobar (typically due to cerebral amyloid
angiopathy) or deep (typically related to hypertension)
and may also be related to rupture of an aneurysm or
arteriovenous malformation, or other aetiologies
(Table 3).
Surgical or radiological procedures such as carotid
endarterectomy and stenting, and closure of PFO and
the atrial appendage, are highly operator dependent.
Success rates should be monitored and are dependent
on proper training and mentoring, and on performing
an adequate number of procedures each year.
Patients require long-term follow-up to monitor
adherence to therapy and the development of cerebro-
vascular events. Typically, this is done in the commu-
nity, but the use of home-based point-of-care devices
and wearables may improve follow-up data collection
and diagnosis of subsequent events.
Most patients benefit from investigation and preven-
tative interventions after a stroke or TIA, and advanced
age is not a contraindication. However, patients with
significant frailty, dementia or dependency might be
spared some prevention strategies by taking account
of their wishes and those of their family. Patients with
stroke or TIA often have co-existing cardiac, renal or
peripheral arterial disease, and this needs investigation
and treatment. Depression and anxiety can be detrimen-
tal to lifestyle and adherence and are risk factors for
stroke and dementia.
Table 2. Recommendations for the investigation of incident or recurrent stroke.
Stroke type Aim Investigation
All Ischaemic vs.
haemorrhagic
CTCTA, or MRIMRA, scanning immediately on admission
to hospital
Vital measures Blood pressure, weight/body mass index
Blood tests Lipids, glucose, HbA1c, coagulation, markers for vasculitis and con-
nective tissue disorders
Severe high BP For secondary causes of hypertension
Ischaemic/TIA Large artery stroke Carotid ultrasound (extracranial)
CT and CTA, or MRI and MRA
Atrial fibrillation ECG
Prolonged arrhythmia recording
Embolic stroke Echocardiography and bubble contrast transcranial Doppler if per-
formed locally
Intracerebral
haemorrhage
CTA or MRA; digital subtraction angiography if appropriate. Interval
blood-sensitive MRI
Subarachnoid
haemorrhage
CT and CTA, lumbar puncture; digital subtraction angiography if
appropriate. Delayed CTA or MRA
Note: Investigations may not be relevant or appropriate in all patients, e.g. those with dependent dementia or other causes of a reduced
life-expectancy.
BP: blood pressure; CT: computed tomography; CTA: computed tomography angiography; ECG: electrocardiogram; HbA1c: glycated haemoglobin;
MRA: magnetic resonance angiography; MRI: magnetic resonance imaging.
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State of current services
Although there is wide variation in the provision of
secondary prevention across Europe, accurate
country-specific data are not available for most inter-
ventions, and published data are usually 5–10 years
old. This indicates an urgent need for more accurate
monitoring and reporting of secondary prevention
(Appendix 2). Available data suggest that more than
60% of patients presenting with a stroke are hyperten-
sive; although 80–90% of these are treated, fewer than
40% will have their blood pressure adequately con-
trolled. Reasons for inadequate blood pressure control
include a lack of monitoring, under-treatment and low
adherence rates. Similarly, although statin prescription
rates on discharge from hospital are high, long-term
adherence rates are low. Furthermore, many patients
with AF still do not receive oral anticoagulation.
Research and development priorities
For all patients
• Do technological solutions improve compliance?
• Do biomarkers identify patients at high of stroke
recurrence and improve secondary prevention?
• Can identification of non-responders to antithrom-
botic therapy improve secondary prevention?
• Can prevention be enhanced in patients taking rec-
ommended prophylaxis?
• Which preventive measures are beneficial in the
very old?
Table 3. Effective secondary prevention interventions and their targets according to type of stroke.
Stroke type Intervention
All • Primary prevention measures are applicable to secondary prevention
• Government campaigns, e.g. promoting healthy lifestyle, reducing air pollution
• Stop smoking (nicotine replacement) and added salt, moderate alcohol intake and weight,61 and
increase exercise62 and consumption of a stroke-protective diet including fruit and vegetables
• Treat high blood pressure with angiotensin-converting enzyme inhibitors or angiotensin receptor
antagonists, calcium channel blockers and/or thiazide-like diuretics;63 usually needs 2 agents to
reach target of <130/80 mmHg (if tolerated). Patients needing 3 drugs to reach target should
be investigated for secondary causes of hypertension
• Glucose lowering in diabetes mellitus. Pioglitazone may provide prevention benefits beyond
glucose control
• Sex-specific differences exist related to menopause and andropause, e.g. certain types of hor-
mone-replacement therapy may increase the frequency and severity of stroke
Ischaemic stroke/transient
ischaemic attack
• Antiplatelet for non-cardioembolic stroke (e.g. AF).64 Dual therapy based on aspirin and clopi-
dogrel for three weeks in acute minor stroke and TIA-, then mono-therapy, or aspirin and
dipyridamole, is relevant for lacunar infarction
Large artery disease • Lipid lowering with a statin, ideally at maximum dose.65 Fibrates, ezetimibe or PCSK9 inhibitors
may be prescribed if statins cannot be tolerated or give insufficient response
• CEA or carotid stenting for symptomatic severe ipsilateral carotid stenosis (NASCET score
70%) or in most high-risk patients with moderate stenosis (50–69%), as soon as the patient is
stable and within two weeks.66 If CEA is not possible, or in younger patients, extracranial carotid
artery stenting is an alternative for high-risk carotid stenosis
Cardioembolic stroke • In atrial fibrillation, NOAC rather than with warfarin or other vitamin K antagonists.67 Although
currently on-patent and therefore more expensive, NOACs have no prothrombotic properties
on initiation, provide more consistent anticoagulation, reduce the risk of intracranial haemor-
rhage, do not need monitoring and have less interactions with food and other drugs
• In patients with likely embolism (no lacunar or large artery features), cardiac echocardiography
(or bubble transcranial Doppler) should be performed. Device closure of PFO68 with a moderate
to large shunt or an atrial aneurysm reduces recurrent events in patients <60 years
Lacunar stroke • Optimise control of blood pressure, blood glucose and lipids and mono-antiplatelet therapy
Other determined aetiology • These include cervical artery dissection, cerebral venous thrombosis, recreational drugs and
genetic mutations and require specific investigation and treatment (in addition to treatment as
defined in ‘All’ above)
Intracerebral haemorrhage • Lower raised blood pressure (as above)
Subarachnoid haemorrhage • Stop smoking, moderate alcohol intake and lower raised blood pressure (as above). Non-invasive
screening for first-degree family
Note: Interventions may not be relevant or appropriate in all patients, related to adverse events, concurrent conditions (e.g. dependent dementia).
AF: atrial fibrillation; CEA: carotid endarterectomy; NASCET: North American Symptomatic Carotid Endarterectomy Trial; NOAC: non-vitamin K oral
anticoagulant; PCSK9: proprotein convertase subtilisin/kexin type 9; PFO: patent foramen ovale.
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• What preventive therapies are effective in sporadic
small vessel (lacunar) stroke and monogenic cere-
brovascular disorders, such as CADASIL
(Cerebral Autosomal Dominant Arteriopathy with
Subcortical Infarcts and Leukoencephalopathy)
and Anderson Fabry disease?
Healthcare delivery
• Should patients with a minor stroke or TIA be rap-
idly assessed in a fast-track one-stop TIA clinic or in
the stroke unit following admission?
• Should all patients be followed up long-term, e.g. at
one year?
Lifestyle and risk factors
• What is the optimal blood pressure target for each
type and subtype of stroke?
• Does treatment of sleep apnoea reduce
stroke recurrence?
• Which nutritional interventions physical activities
reduce stroke recurrence?
Large artery atherosclerosis
• Does best medical therapy obviate the need for
carotid intervention in asymptomatic patients?
• Are new antithrombotic strategies required?
• Will advanced stenting procedures further
reduce recurrence?
• Will new lipid-lowering drugs further reduce
stroke recurrence?
• Should patients be investigated for asymptomatic
atherosclerosis?
• What is the optimal treatment for intracranial ste-
nosis causing recurrent events?
Cardioembolism
• Which patients benefit from PFO closure?
• What is the optimal treatment strategy in patients
with AF and a high risk of ischaemic and haemor-
rhagic stroke?
• What is the optimal time to start oral anticoagula-
tion after AF-associated stroke?
• How should patients with AF and atherosclerosis
be treated?
SVD
• How can SVD-related cerebral lesions and their pro-
gression be prevented?
• Should the presence or burden of SVD lesions influ-
ence secondary prevention decisions?
Cryptogenic stroke/embolic stroke of undetermined source
• Which preventive therapies are effective?
ICH
• Which patients with AF on oral anticoagulants can
be restarted with oral anticoagulants following ICH?
• When should statins be (re-)started after ICH in
patients with ischaemic vascular disease?
SAH
• Understand the mechanisms of aneurysm formation
and rupture in order to prevent recurrent SAH.
Targets for 2030
1. Including secondary prevention in national stroke
plans with follow-up in primary/community care.
2. Ensuring that at least 90% of the stroke population
is seen by a stroke specialist and have access to sec-
ondary prevention management (investigation
and treatment).
3. Ensure access to key investigational modalities: CT
(or MR) scanning, carotid ultrasound, ECG, 24-h
ECG, echocardiography (transthoracic and transoe-
sophageal), blood tests (lipids, glucose, HbA1c,
coagulation, erythrocyte sedimentation rate,
C-reactive protein and autoantibodies).
4. Ensuring access to key preventative strategies: life-
style advice, antihypertensives, lipid-lowering
agents, antiplatelets, anticoagulants, oral hypogly-
caemic agents and insulin, carotid endarterectomy
and PFO closure.
Rehabilitation
State of the art
In the Helsingborg Declaration of 2006,3 the goal for
2015 was that all stroke patients in Europe would have
access to a continuum of care from acute management
to appropriate rehabilitation, delivered in dedicated
stroke units.
Among adults, stroke is the most common cause of
new disability leading to more than one impairment
that could affect daily activities (Table 4).
Rehabilitation has been defined by the WHO as ‘a set
of measures that assist individuals, who experience or
are likely to experience disability, to achieve and main-
tain optimal functioning in interaction with their envi-
ronments’.69 It is instrumental in enabling people with
functional limitations to remain in or return to their
home or community, live independently and participate
in education, work and civic life. The United Nations
Convention on the Rights of Persons with Disabilities
(UNCRPD) includes the right to rehabilitation,70 but
the 2017 SAFE report on Stroke in Europe8 has clearly
shown that access to rehabilitation varies across
Europe. In the same year, WHO made a call for
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action, ‘Rehabilitation 2030’, to address the significant
rehabilitation needs across the world and the substan-
tial apathy towards these needs shown by many
governments.71
Care in hospital – stroke units and early rehabilitation. Acute
stroke care, skilled nursing care and specialist rehabili-
tation are all core aspects of a comprehensive stroke
unit, and treatment in such facilities has been shown
to reduce mortality and disability.31 Rehabilitation
includes occupational, physical and speech and lan-
guage therapy, with input from psychologists and
social workers as necessary. It should involve a multi-
disciplinary approach from stroke physicians in a com-
prehensive stroke team, and an ordered plan for
discharge from hospital with documented responsibility
for continuing rehabilitation needs in the community.
Patients and carers need information about stroke,
rehabilitation and planned discharge and follow-up.72
This information improves knowledge, patient satisfac-
tion and reduces depression. How this information is
best delivered remains unclear, but active involvement
of both patients and family members seems to
be beneficial.
Transition from hospital to home – early supported discharge
and community rehabilitation. ESD34,35 is an innovative
approach to rehabilitation, in which services are pro-
vided at home by a mobile rehabilitation team, and
should be seen as a part of the stroke treatment path-
way. The target audience is mainly patients with mild
or moderate stroke symptoms, which includes about
30% of the stroke population in most settings.
Studies show that access to ESD services reduces
length of hospital stay by a mean of six days and
reduces the odds of being dead or dependent after
stroke by 20%. Patients with moderate to severe
stroke should still have access to stroke rehabilitation,
either during a prolonged stay in hospital or with ade-
quate rehabilitation to address their needs in
the community.
As recovery continues and stamina increases, the
intensity of training may increase. For patients with
aphasia, this can mean high-intensity training over a
prolonged period, which has proven effective in terms
of improved functional communication, reading, writ-
ing and expressive language.73
There is evidence that continued ADL training in
the home setting after discharge has a beneficial effect
for up to one year after stroke.74 Different modes of
rehabilitation delivery during the first year, such as
domiciliary, day-case hospital care and home-based
care have been shown to improve independence in per-
sonal ADL.
Stroke survivors are often physically deconditioned,
with muscle weakness in both the affected and unaf-
fected sides, and impairments in cardiorespiratory fit-
ness. Physical fitness training after stroke reduces
disability, improves walking ability and may improve
other stroke-related deficits such as cognition, mood
and fatigue.75,76 Access to green areas and walking
space may facilitate physical activity.77–79
Later rehabilitation and reintegration. Whether rehabilita-
tion provided for more than one year after a stroke
can improve recovery remains unclear. People who
are recovering from a stroke often have persistent dis-
abilities after one year or more. A Cochrane review has
found that there are few studies in this area, and hence
data are inconclusive, although there appears to be a
tendency towards improved recovery with rehabilita-
tion.76 However, targeted training, such as balance
training, gait training with different devices, and
upper extremity training more than one year after
stroke seems to have a positive effect.75,80–82
Language training in specific groups or with computer
programs has also been reported to be beneficial. This
can be performed in peer-support patient organisation
groups, or in other forms of group training.83 For
younger persons, returning to work raises issues of
identity and quality of life, as well as a means of
living; hence, access to vocational rehabilitation is
Table 4. Distribution of neurological deficits after stroke.a
Affected area Frequency Consequences Treatment
Motor function 50–85% Impaired balance, transfer ability, walking and
reduced upper extremity function
Task-specific repetition training seems
most beneficial
Cognition 1/2 Memory problems, reduced attention, execu-
tive dysfunction and spatial neglect
May affect the person’s ability to manage
daily life.
No clear evidence of beneficial inter-
ventions. So far, often-compensatory
strategies seem to work best
Communication 1/3 Aphasia, ranging from occasional word-finding
difficulties to having no effective means of
verbal communication
Information to patient and family in the
acute setting
aMany persons with stroke have more than one impairment. In addition, anxiety and depression are common after stroke.
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important for patients in whom a return to work
seems possible.84
It is important to recognise that improvement can
continue for a long time after stroke, and that the
patient’s needs will vary over time. Therefore, it is
never too late for rehabilitation.
State of current services
There is large variability in access to rehabilitation
between and within countries in Europe. These differ-
ences probably reflect international differences in the
organisation of stroke services, strategic approaches to
stroke and available resources. Comprehensive stroke
units are still lacking in many countries, and the slow
rehabilitation documented in stroke unit trials is almost
absent. Patients with moderate to severe stroke benefit
even more from stroke unit care. If this is not possible,
the stroke rehabilitation unit provides an evidence-
based alternative for continuing in-patient treatment.
There is a need to increase the number and capacity
of comprehensive stroke units, in order to ensure that
all patients have equitable access. There is also a short-
age of rehabilitation and nursing staff with expertise in
stroke and an understanding of rehabilitation.
Rehabilitation in a comprehensive stroke unit should
be available at all times.
There is a shortage of ESD services in all European
countries, and in some areas, this is not offered as part
of the stroke pathway. Similarly, physical fitness train-
ing programmes are not common in Europe but are
now being developed in Italy and the UK.
Research and development priorities
• How can we efficiently implement long-term rehabil-
itation strategies, including measures such as ESD?
• How can we deliver more cost-effective long-term
rehabilitation?
• Do self-management programmes improve long-
term outcomes of stroke rehabilitation?
• How can rehabilitation be implemented with
evidence-based results on timing, level and type of
intervention?
• How can we improve participation and integration
into society among stroke survivors?
Management of neurological deficits
• Can post-stroke fatigue be more effective-
ly managed?
• Can post-stroke visual problems be more effective-
ly managed?
• Can post-stroke language problems be more effec-
tively managed?
• Can post-stroke cognitive impairment be more effec-
tively managed?
• Can depression or anxiety be more effective-
ly managed?
• Can post-stroke upper limb problems be more effec-
tively managed?
• Can rehabilitation in an enriched environment
improve outcome?
Targets for 2030
1. Guaranteeing that at least 90% of the population
have access to early rehabilitation within the
stroke unit.
2. Providing ESD to at least 20% of stroke survivors in
all countries.
3. Offering physical fitness programmes to all stroke
survivors living in the community.
4. Providing a documented plan for community reha-
bilitation and self-management support for all
stroke patients with residual difficulties on discharge
from hospital.
5. Ensuring that all stroke patients and carers have a
review of the rehabilitation and other needs at three
to six months after stroke and annually thereafter.
Evaluation of outcomes and quality
improvement
State of the art
Background. There are huge variations in the quality of
care for stroke patients in Europe, both between and
within countries. This is partly due to differential access
to resources, but often it is due to less easily explained
differences in the organisation and delivery of care. The
goal set for 2015 in the Helsingborg Declaration of
2006 was that all countries should establish a system
for the routine collection of data needed to evaluate the
quality of stroke management including patient safety
issues.3 This has been only partially achieved, but there
is evidence of benefit in those countries that have suc-
cessfully implemented quality improvement pro-
grammes. The Action Plan for Stroke in Europe
2018–2030 aims to raise the overall standards of care
that patients can expect, in accordance with interna-
tional evidence-based practice and to enable weaker
services to improve.
Guidelines. Comprehensive guidelines need to be devel-
oped and used to set standards for clinical services.
While international guidelines such as the ESO stroke
guidelines can form the basis for national guidelines,
these need to be adapted for use within different health
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systems. The guidelines should form the basis for devel-
oping audit standards.
Measuring quality (audit). Clear standards and assessment
of the quality of stroke services are essential if quality
improvement is to be achieved. This information is
needed to allow individual clinicians to monitor and
modify their practice, for stroke services (hospital and
community), for funders of healthcare to ensure that
funded services are being adequately delivered, and for
healthcare planners at national and international level.
Additionally, it is important that the results of quality
monitoring, with appropriate interpretation, are made
available to patients and the public, to provide assur-
ance that high-quality care is being delivered. If valid
and reliable comparisons are to be made between serv-
ices nationally and internationally, it is essential that
definitions and terminology are standardised across
countries. One of the reasons for apparent differences
in incidence and outcomes after stroke is that different
countries collect and report data in different ways. This
is particularly evident with the definition of TIA, but
there are also variations in the way that International
Classification of Diseases (ICD) codes are used to clas-
sify stroke.
To fully describe a service, data are needed on the
structure of stroke services (facilities, staffing, etc.), on
the processes of care (door to needle times, intensity of
rehabilitation provided, time to get to a stroke unit,
etc.) and outcomes (mortality, physical, cognitive and
psychological disability, frequency of complications
such as pneumonia, etc.). The measures used should
address aspects of care for the whole patient pathway,
including acute care, rehabilitation, post-hospital care
and secondary prevention. It is important both to
record the care provided and the patients’ experience
of care and patient-reported outcomes. Registry data
can be a powerful research tool to confirm that rand-
omised controlled trial (RCT) evidence is transferable
to routine services and can be used to address questions
that could never be tested in RCTs.
Supporting improvement. Different audit models have
been used across Europe, ranging from ‘snapshot
audit’ where a consecutive cohort of patients have
their care quality measured for a short period to
audits that attempt to collect data on all stroke
patients. However, collecting and reporting data
alone is not sufficient to produce quality improvement:
support is needed to enable change. This may involve
local clinical leadership, managerial support, external
help through peer review and sometimes the provision
of additional resources. Sometimes, a major service
reconfiguration may be required.
State of current services
Health service structures and payment systems often
determine the pathways of care. The organisation of
stroke services varies considerably around Europe,
with stroke patients being managed within general neu-
rology services, by full-time stroke specialists, or within
general medical services. Specialist care is common for
the hyperacute phase of treatment, but rehabilitation is
more often managed separately within generic rehabil-
itation facilities. Community care is even more diverse,
with few countries extending specialist care to domicil-
iary services. Few countries or regions have appointed
a national clinical lead for stroke, with the exception of
England, Scotland and Ireland. National guidelines for
stroke management have been produced in many coun-
tries, including the UK, Sweden, the Republic of
Ireland, Spain, France and Italy. In addition, some
European Guidelines have been developed to cover
specific aspects of stroke care, and others are in
development.85
There are few international comparisons of care that
are based on high-quality data. The 2017 SAFE report8
is the most up-to-date picture of stroke care in Europe
but does not address quality of care. However, based
partly on the Global Burden of Disease studies, it does
show large variations in case fatality rates, which range
from 3% in Denmark to 18% in Latvia.8 Research
studies, some funded by the EU, have compared
stroke care in different countries, but these are usually
performed at individual hospital level rather
than nationally.
Comprehensive stroke quality registers (with partic-
ipation from all hospitals treating acute stroke
patients) are available in some countries and regions,
including Sweden, the UK, Germany, Catalonia, the
Republic of Ireland, the Netherlands, Norway and
Finland. A quality register is operating in Eastern
Europe (RES-Q), which is rapidly recruiting participat-
ing centres. However, only Sweden and the UK
attempt to provide data for patients after leaving hos-
pital, and few countries make the quality data available
to the general public. Regional, rather than national,
initiatives for quality improvement are in place in some
countries, such as Spain and Italy, and this can result in
significant within-country variations in care quality.
Quality indicators for stroke have been published in
France and Turkey, and a consensus paper on core
standards for measuring quality has been published.86
Research and development priorities
1. What definitions should be used across Europe for
the recording and reporting of data on stroke
and TIA?
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2. What are the most effective and efficient systems for
the collection of data on the quality of stroke care
across Europe?
3. How can data on the quality of care be used to com-
pare process and outcomes of care, taking into
account variations in case-mix, and what is the min-
imum dataset that is needed?
4. What are the systems needed to allow international
comparisons of the clinical and cost-effectiveness of
care, and reporting of within-country variations and
variations by other factors such as geographical
region (urban versus rural), and variations
over time?
5. What are the most effective quality improvement
tools that will enable learning from examples of
best practice?
Targets for 2030
1. Defining a Common European Framework of
Reference for Stroke Care Quality that includes:
(a) development or update of European guidelines
for management of acute stroke care, longer term
rehabilitation and prevention; (b) definition of a
common dataset covering core measures of stroke
care quality to enable accurate international com-
parisons of care both in hospital and in the commu-
nity (including structure, process, outcome measures
and patient experience).
2. Assigning a named individual who is responsible for
stroke quality improvement in each country
or region.
3. Establishing national- and regional-level systems for
assessing and accrediting stroke clinical services,
providing peer support for quality improvement
and making audit data routinely available to the
general public.
4. Collecting patient-reported outcomes and longer
term outcomes (e.g. six months and one year), cov-
ering both hospital and community care.
Life after stroke
State of the art
Life after stroke was not addressed specifically in the
2006 Helsingborg Declaration,3 because historically it
has been largely considered as an aspect of rehabilita-
tion: however, it has become increasingly apparent that
this area merits recognition in its own right. Life after
stroke is a large and overarching domain, and includes
those who had a stroke in childhood (for whom it rep-
resents an entire lifespan) as well as those who had their
stroke later in life. The domain includes consideration
of family, friends and others who provide care and
support for the stroke survivor, and whose own quality
of life is also potentially affected; it covers stroke sur-
vivors living at home and in institutional homes.
Life after stroke has only been regarded as a sepa-
rate entity in recent years. As a result, there are rela-
tively few research studies covering the entire lifespan,
and those that do tend to focus on reporting outcomes
from rehabilitation interventions. Few of the current
adult UK guidelines specifically address longer term
stroke management,87 reflecting the paucity of evidence
in this area. The World stroke Organization (WSO) has
identified evaluating the best ways to address and
improve life after stroke as a stated priority, although
to date, this has not been adequately addressed.88
Similarly, the Global Stroke Bill of Rights89 also
underlines the importance of providing longer term
support. However, in reality, there is relatively little
reference to life after stroke in national guidelines.
The few studies identifying long-term consequences
after stroke report that around a third of stroke survi-
vors are disabled, have poor post-stroke cognitive abil-
ity and poor mental health. From stroke survivors’
own perspectives, surveys show that they also experi-
ence unmet needs in terms of communication, social
relationships, loneliness, incontinence, fatigue and
finances.90,91 It has been estimated that one in four
strokes occur in people aged 65 and under,92 whose
needs may also include support to return to work.
There is also parallel emerging evidence of the pro-
found and long-term impact on carers; a 2013 report
from the UK Stroke Association found that 80% of
informal carers experienced anxiety, and that there
were significant strains on relationships, with 1 in 10
people experiencing a breakdown of their relationship
with their partner.93 There are also indications that
there are growing numbers of young carers providing
support for parents.
Qualitative research, and the Burden of Stroke in
Europe Report,8 have documented the everyday
plight of some survivors and their families. However,
much of this information has not been collected sys-
tematically or rigorously, and there are countries for
which there is no information available. Nevertheless,
the illustrative texts paint a complex picture of life after
stroke, and for many, it would seem that coping is
tackled on an ongoing, daily basis with recognition
that ‘it’s a new life; you have to adjust to what you can
do’.8 There are also documented effects on family mem-
bers (‘. . .people are very lonely after they have lost these
abilities [physical functions]. . . .. The families are very,
very tired’) and family members (‘No one explained to
my partner what it was going to be like moving forward,
what the consequences might be, what they might not
be’).8 Thus, although some survivors report positive
experiences from changing their priorities after
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stroke, from focusing on relationships, and from deep-
ened experiences, for many, there are significant
day-to-day challenges. With an increasingly ageing
population and more people surviving a stroke, it is
therefore vital that stroke survivors and their families
are empowered to optimise their quality of life and
attain their maximum level of independence. This
must be considered in relation to home, education
and work, according to the stage of the person’s life
and their individual priorities. It is also important that
this is considered in relation to other long-term condi-
tions such as diabetes, hypertension, AF, depression,
cognitive impairment, epilepsy, pain and spasticity.
However, there is little robust evidence to support dif-
ferent approaches or models of care, and no agreement
on what is meant by long-term survival: studies include
people from six months to more than 20 years post-
stroke as ‘long-term survivors’. Furthermore, no recog-
nised scale exists to measure participation of stroke
survivors in community activities.
The current literature lends itself to considering the
issues surrounding life after stroke under four overlap-
ping categories: health issues, activity issues, adjust-
ment and wellbeing and information and support
issues (Table 5). General principles surrounding these
issues include: recognition by society of the worth and
value of those with disabilities, including the impor-
tance of community integration and legislation; the
need for a care plan after formal rehabilitation ends;
the need for a seamless, structured and co-ordinated
chain of support (still encompassing individual and tai-
lored options) and the provision of services across
the lifespan.
Life-long services required after stroke include
access to ongoing diagnostics, therapy, medication,
psychological support, rehabilitation and equipment
as required, regular review and access to family support
and self-management strategies. Figure 1 shows graph-
ically how these might be integrated, as described in the
2007 UK National Stroke Strategy from the UK.94
State of current services
There are relatively few robust data available across
Europe on longer term management and care after
stroke. Where data exist, collection has been relatively
unsystematic, and the service data are therefore both
patchy and anecdotal; little attention has been paid to
developing, let alone evaluating, longer term care.
Stroke survivors seem ill prepared for the transition
from rehabilitation, and many studies report survivors
and their carers feeling ‘abandoned’.95 There is evi-
dence of six-month reviews being conducted in some
European countries, but there is a conspicuous reduc-
tion in data from survivors or their carers beyond this
Table 5. Life after stroke issues.a
Health issues
• Specific post-stroke disabilities, e.g. arm function, vision,
dysphagia, spasticity (need for ‘top up’ in rehabilitation;
regular review and equipment)
• Hidden post-stroke deficits, e.g. psychological, cognitive,
depression, anxiety, communication, fatigue and
incontinence
• Co-existing conditions including frailty and dementia
(medication implications) and associated with old age,
e.g. hearing
• Need for links to secondary prevention in primary care,
e.g. medication, diet and exercise
• Emergence of sequelae over time, e.g. epilepsy
and depression
• End of life care
Activity issues
• Meaningful activities including leisure, holidays and play
• Vocational support – getting back to work or education
• Mobility including driving, transportation and access
• Vocational support – getting back to work/education
• Role in family and society (issues regarding relationships
and divorce)
• Friendships – making and keeping friends
• Key life transitions, e.g. entering school, discharge from
rehabilitation
• Communication
Adjustment and wellbeing issues
• Coming to terms with new life
• Specific individual issues, such as sex, sleep, fatigue
and confidence
• Happiness/life satisfaction/loneliness
• Grief and adjustment of parents/carers for changed
future prospects
• Emotional, behavioural and psychosocial domains
of wellbeing
• Environmental including nursing home/residential care
Information and support issues for individual and carers/parents
• Self-management (includes parent education to support
their child)
• Advocacy psychological and emotional support
• Communication-including aphasia friendly and culturally
sensitive literature
• Cognitive support, e.g. memory and concentration
• Financial support including benefits. Issues re-additional
costs of stroke
• Long-term support groups, peer support and volunteering
• Community integration – loneliness/isolation
• Practical help with specific tasks, e.g. housework
and shopping
• Carer support (including children–parents and siblings;
parents–siblings, relationship support for partners) and
respite care
• Specific support, e.g. around return to work.
• IT access support; web-based interventions, tele- rehabili-
tation, podcasts on life after stroke/audiobooks, virtual
reality-based support
• Sharing of relevant information across health, education,
work and social care with the appropriate consents of the
patient and carers
• Proactive review
aThis is not an exhaustive list, but merely an indication of the breadth and
depth of issues faced across the lifespan after stroke: many issues will
overlap between categories.
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time. Similarly, there is no Europe-wide agreed model
for the long-term support for children or young people
who have had a stroke. Their needs, and those of their
families, are typically provided by community services
that usually also cover cerebral palsy, acquired brain
injury and allied neurological conditions. However, it is
rare for a child to receive intensive residential rehabil-
itation services after discharge from hospital. Families
may have access to specialist tertiary level support
around the time of diagnosis, but continuing access
to this support varies and typically tapers off over
time. Overall, there appears to be little evidence of
holistic and coordinated support. There is no pathway
for survivors, who often find themselves on parallel
paths for other conditions (e.g. depression and diabe-
tes); longer term review may enable stroke survivors
and their carers to better follow their individual disease
management plan. Most importantly, there is no model
of what best care looks like following discharge from
specialist services. The large and growing number of
stroke survivors with long-term needs must be
addressed; we need to develop minimum standards of
care and measure these.
There is a growing interest in collecting patient-
reported outcome measures (PROMs) data that
would best reflect patients’ views about their care and
provide additional information beyond the traditional
clinician-reported measures. Patient representatives
have played an important role in the development of
these measures. The American Heart Association has
advocated broader use of PROMs in both clinical prac-
tice and research.96 Similarly, the Swedish Stroke
Register97 has gradually broadened to more fully
cover the quality of services and late outcomes after
stroke, through follow-up at three months and at one
year after the event.98 There is an emphasis on PROMs
Figure 1. Range of support needed after stroke.94*
*This model was worded specifically for adults.
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relating to ADL, self-perceived health, health-related
quality of life, mood, pain, satisfaction with stroke
services, rehabilitation and community support; all of
these are important for stroke survivors. Questions
about the need for support for the carer may also
be included.
Research and development priorities
• What are the experiences and needs of stroke survi-
vors at different times during their lifespan?
• What are the needs of different cohorts of stroke
survivors? This needs to include patient- and carer-
reported outcomes, and to address the challenges of
stroke survivors with multiple morbidities, and their
carers, in order to enable the design of optimal
care pathways.
• What would a model of best care and long-term
support look like? This should include the provision
of three to six-month and annual reviews and spe-
cific roles to provide holistic coordinated support.
• What products and services (digital and physical)
would support self-management, community inte-
gration, education and healthcare?
• How can high-quality information and training to
help non-specialist staff, especially social care staff,
be targeted? It is envisaged that this will involve
research around staffing levels, core competencies
and the involvement of non-governmental and
non-profit-making bodies such as charities and vol-
untary groups.
Targets for 2030
1. Appointing government-level individuals or teams
responsible for championing life after stroke and
ensuring that national stroke plans address survi-
vors’ and their families’ long-term unmet needs.
Minimum standards set for what every stroke survi-
vor should receive regardless of where they live.
2. Formalising the involvement of stroke survivors and
carers, and their associations, in identifying issues
and solutions to enable the development of best
patient and support practices.
3. Establishing, through national stroke care plans, the
support that will be provided to stroke survivors,
regardless of their place of residence and socioeco-
nomic status.
4. Supporting self-management and peer support for
stroke survivors and their families, by backing
stroke support organisations
5. Supporting the implementation of digitally-based
stroke self-help information and assistance systems.
Prioritised research areas for translational
stroke research
State of the art
Clinical discoveries have resulted in huge improve-
ments in the management and treatment of acute
ischaemic stroke patients. There have been advances
in understanding the pathophysiology of stroke and
chronic cerebrovascular diseases,99 but the goal of
translating this knowledge into successful treatments
has not been achieved. The efficacy of mechanical
thrombectomy increases the potential for successful
translation of neuroprotective agents. Technological
developments offer new opportunities for deciphering
pathophysiological processes underlying cerebrovascu-
lar diseases, identifying novel targets for drug therapies
and drug repurposing. There is also increasing interest
in personalised medicine approaches utilising geno-
mics, imaging and other biomarkers for stratification
of stroke patients. However, novel opportunities run
the risk failing in translation, unless accompanied by
conceptual changes in the way research is performed.
Bridging the ‘translational gap’ between basic and
clinical stroke research is critical for the development
of effective treatments. Key requirements here include
improved networking between laboratory scientists and
clinicians, better experimental designs and the develop-
ment of more relevant experimental models that mirror
the complexity of human diseases.100 The disappoint-
ing outcome of translation in the last decades demands
novel methodological strategies.101,102
The following sections highlight major research
topics where recent advances offer new opportunities
for translational studies, where there is urgent need for
therapeutic strategies, or both. Next, we analyse critical
problems in the current pipeline of translational
research and suggest action points aimed at changing
conventional practice by designing novel strategies to
tackle translational bench-to-beside research.
Key translational research topics
Reperfusion. Current optimal treatment for acute
ischaemic stroke is recanalisation with intravenous
tPA, endovascular treatment or both. However, micro-
vascular reperfusion is not always achieved, not all
patients benefit from endovascular treatment, and
many patients are not eligible for reperfusion therapies.
Improving tissue reperfusion: Strategies designed to
dissolve thrombi or prevent thrombus formation local-
ly in the capillary bed should be investigated, either
alone or in combination with mechanical recanalisa-
tion. Recent research has identified cellular and
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molecular targets that may help achieve optimal reper-
fusion according to clot composition and location.
Reducing reperfusion injury: Secondary complica-
tions of reperfusion therapies, such as haemorrhagic
transformation, should be minimised. Complications
due to previous treatments, such as antiplatelet drugs
and anticoagulants, and the effective use of antidotes,
require further investigation. Current experimental evi-
dence suggests that oxidative or nitrosative stress and
thrombo-inflammation103 impair the benefits of reper-
fusion, but this concept awaits translation to the clinic.
Protective drugs for treatment and prevention.
Neuroprotection: Translation of drug treatments to
the new clinical recanalisation scenario offers opportu-
nities for novel and old drug candidates that have failed
in the past when administered too late or in the absence
of reperfusion.104 The concept of neuroprotection has
evolved because protection is needed for functional
units composed of neurons, glial cells, pericytes, mac-
rophages and the vasculature. Approaches to protect-
ing the white matter, which is under-represented in
most animal models of stroke, need further
development.
Vascular protection: Protecting the vasculature is
critical in ischaemia and reperfusion since the vascula-
ture plays a major role in propagating injury through
both acute and chronic vascular dysfunction. A good
collateral circulation can reduce infarct size and sec-
ondary growth by supplying blood to the penumbra,
but we still do not know how to effectively modulate
collateralisation for preventive or acute therapy.
Detailed investigation, using advanced imaging techni-
ques and vascular biology research, is required to
obtain data on vascular integrity, haemodynamic
responses and blood–brain barrier (BBB) function.
Inflammatory and immune responses. Promising cellular
and molecular inflammatory mechanisms, with poten-
tial impacts on acute stroke outcomes and post-stroke
recovery, have been identified.105 However, substantial
basic research is required for a more comprehensive
understanding of the complex neuro-immune interac-
tions before translational strategies are attempted.
Chronic inflammation has emerged as an important
pathogenetic mechanism in neurodegenerative and
chronic cerebrovascular diseases, and may be relevant
for cognitive decline and dementia.106 Stroke triggers a
multiphasic systemic inflammatory response that
involves neural signals and soluble mediators, includ-
ing cytokines, vasoactive substances, alarmins and
acute phase proteins, followed by an inhibition of
immune responses that increases the risk of post-
stroke infection. Imbalance of peripheral immune
homeostasis after stroke represents a promising
therapeutic target that requires investigation.
Repurposing of available drugs in clinical use for
other inflammatory conditions could improve the
translational efficacy in testing anti-inflammatory ther-
apies for stroke.107
Intracerebral haemorrhage and SAH. New cellular and
molecular processes, including inflammation, are rec-
ognised as critical players for brain damage after
ICH.108 A genetic contribution to these processes has
been identified and requires exploration in experimen-
tal models, as well as translation to pharmaceutical
targets. Research in ICH is particularly needed given
the devastating clinical consequences of ICH and the
current lack of treatment options for this condition.
Appropriate experimental models of ICH and SAH,
and models mimicking aneurysm rupture, are required.
Mechanisms of early ischaemic damage preceding
vasospasm after SAH should be investigated.
SVD. Specific treatments for established SVD are lack-
ing, despite its enormous health importance as the
cause of 20% of ischaemic strokes, and a major cause
of intracerebral haemorrhage, vascular cognitive
impairment or dementia. Incomplete understanding
of SVD pathogenesis and a lack of appropriate
animal models are obstacles to progress. Large-scale
studies of systems biology can provide insights into
the underlying mechanisms of complex diseases and
responses to treatment.109 Key priorities in this area
include: better understanding of the pathogenic contri-
bution of endothelial dysfunction or BBB disruption,
inflammation and hemodynamic factors; understand-
ing the role of proteins and pathways involved in
monogenic forms of SVD and (multifactorial) sporadic
SVD;110 understanding the mechanisms leading to cog-
nitive impairment and deciphering the intricate rela-
tionship with Alzheimer’s disease; designing
protective approaches to reduce progression of white
matter damage; expanding the identification of genetic
and other molecular biomarkers and translating the
new putative targets discovered through genetic, molec-
ular and cellular biology data into disease-
modifying therapies.
Functional recovery and rehabilitation. A key objective is to
expand our knowledge on functional recovery mecha-
nisms and potential therapeutic targets to enhance the
effects of physical rehabilitation in the chronic phase
after stroke. Research is needed on neuronal plasticity
and network recovery, and their interaction with
delayed pathophysiological mechanisms such as neuro-
inflammation, apoptosis, neurogenesis and angiogene-
sis. This will require the adoption of methodology from
stem cell research, gene therapy, optogenetics,
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non-invasive brain stimulation and other fields. The
methodology for evaluating functional recovery in
experimental stroke models should be improved.
Key research pipeline priorities
A critical question is how translational research should
be performed if it is to be successful. Despite promising
novel advances, the field risks propagating the same
methodological errors that have blocked translation
to the present day. A number of crucial strategic
steps are proposed to overcome the block in transla-
tion, and action points relating to these are summarised
in Table 6.
Exploratory versus confirmatory studies. Preclinical research
has traditionally lacked genuine confirmatory studies
for testing treatment efficacy. Instead, exploratory
studies identifying and investigating novel molecular
or cellular pathways and mechanisms were frequently
combined with therapeutic experiments. However,
these are often hampered by insufficient statistical
power and poor designs, resulting in low
reproducibility.
Preclinical, confirmatory studies as an intermediate
translational step. Clinical trials based on preclinical
target identification and drug development have typi-
cally relied on a few small-scale, single-centred and
underpowered studies. As a result, current translational
efforts represent an enormous leap from small explor-
atory studies to large, confirmatory trials in a highly
variable human disease. This huge gap requires an
intermediate step to improve the translational reliabil-
ity and solve the problem of lack of replication.
Improve experimental modelling. An important reason
why translation has failed so far is that current exper-
imental modelling lacks internal, external and con-
struct validity. Experiments are mostly performed in
young, male, genetically identical rodents, housed in
artificial pathogen-free conditions, under anaesthesia.
As a result, they may not accurately reflect the diverse
conditions encountered in clinical medicine.
Adopt a ‘Team Science’ approach. Large-scale collabora-
tions with a ‘Team Science’ approach are needed to
guide further development in translational research.
Clinicians should be partnering with basic researchers
by specifying research needs and contributing to pre-
clinical study design from a clinical perspective.
Initiatives for large-scale preclinical multicentric trials
using, as much as possible, protocols commonly
accepted for clinical trials, have started, but the utility
of this tool remains to be shown.
Improve efficacy of early stage clinical trials. Early-stage
clinical trials represent an intermediate step between
preclinical drug development and large-scale clinical
trials. As such, the designs should keep up with the
pace of preclinical target identification, be sufficiently
sensitive to test novel approaches in a stratified, opti-
mal target population and when possible seek a genetic
rationale for drug effects.
Table 6. Proposed strategic steps for translational research in stroke, with related action points.
Strategic step Action points
Exploratory versus confirmatory studies • High-quality basic research with:
– state-of-the art, rigorous, methodology
– transparency
– data availability (e.g. deposition of protocols/data in public repositories)
– avoidance of publication bias
Preclinical confirmatory studies as an
intermediate translational step
• Separation of discovery and confirmation
• Confirmation before undertaking clinical studies
• Preregistration
• Pre-planned study designs and analyses
• Publication of all results (including negative results)
Improve experimental modelling • Reduce bias
• Increase power
• Include comorbidities
• Less standardisation, more variability (e.g. genetics,
different habitats, ageing and sex)
Change to a larger ‘team’ concept • Establishing ‘Team Science’ in stroke research
Improve efficacy of early stage clinical trials • Regulations should be more proportionate to the risks of the trial
• Carefully stratify patients for clinical trial inclusion, with the perspective
of developing personalised treatment approaches
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Involvement of various parties
Commitment is needed from EU and national funding
agencies to invest in stroke research in a proportionate
manner to the magnitude and prevalence of the health
problem. Strategies designed to validate findings from
exploratory research require a joint effort that exceeds
the capacity of individual projects or small sporadic
collaborative endeavours. Strong independent institu-
tional support is required to make the transition from
classical designs to a novel concept of organised
research structures and data validation that aims to
facilitate reliable translation of preclinical findings to
clinical practice. The pharmaceutical industry should
also be engaged in this process: involvement of phar-
maceutical companies could be increased by facilitating
exchanges between academic and pharmaceutical
research at the point of transition from exploratory
to confirmatory preclinical studies. Finally, researchers
must disseminate their findings to bring stroke research
closer to patient associations and the gener-
al population.
Targets for 2030
1. Achieving an organisational framework by imple-
menting confirmatory preclinical research through
‘Team Science’ and by providing novel instruments
for advanced experimental designs to
increase validity.
2. Establishing and implementing guidelines for pre-
clinical trials of new treatments to maximise the suc-
cess of clinical translation.
3. Focusing experimental stroke research on identifica-
tion of new treatable targets with high translational
potential that lead to successful clinical trials
by 2030.
Conclusions
ESAP provides a comprehensive overview of the cur-
rent state of stroke management, as well as specific
targets and research and development priorities for
stakeholders. The ESAP Implementation Plan will be
drafted after having assessed an updated epidemiolog-
ical report on stroke incidence, prevalence and mortal-
ity and receiving detailed and reliable data from quality
registries from national stroke and patient societies. It
is anticipated that the progress towards the targets and
research and development priorities laid out in this
paper will be reviewed in 2021 and 2024, with a mid-
term review scheduled for 2024. The extent to which
the targets have been achieved will be reviewed in 2030.
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Appendix 2. Issues in secondary
prevention of stroke
Accurate data are scarce, with few countries having
national registries and most published data being
5–10 years old. Hence, there is an urgent need for con-
temporaneous accurate monitoring and reporting. In
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in 2017, there was wide variation in the availability of
evidence-based secondary prevention treatments: in
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Norrving et al. 27
assessed on the same day or within 48 h, usually as an
inpatient or in a dedicated TIA clinic, whereas in some
Eastern European countries TIA patients were still
routinely reviewed in general medical clinics or primary
care, often after more than a week. Although most
patients undergo carotid imaging by ultrasound and
24–48-h monitoring for AF, few countries offer more
prolonged monitoring to the majority of patients, and
assessment by ECG alone remains the commonest
method in some Eastern European countries. Across
Europe, blood pressure after stroke or TIA is most
often assessed by clinic readings and ongoing manage-
ment is commonly devolved to primary care; few coun-
tries regularly use ambulatory or home monitoring of
blood pressure.
Less than half of countries routinely provide lifestyle
management programmes after stroke, although such
programmes are more common in Western Europe;
only smoking cessation programmes are consistently
available, and reimbursement for such programmes is
rare. Adherence to antiplatelet therapy is high, but
after one year, fewer than half of patients are estimated
to be still on statins in some countries. While 60–80%
of patients in the highest performing countries report
blood pressure control at one year, significantly lower
national rates of control are common. Interventional
carotid endarterectomy is widely available, but the time
to treatment is highly variable, from within a week for
patients in the best-performing nations to routine waits
of greater than one month in others. Finally, although
advanced procedures (carotid stenting, atrial append-
age/PFO closure, neurosurgery and radiosurgery) were
more commonly available overall in the west, their use
varied substantially, largely independently of the eco-
nomic background of the reporting nation.
Overall, provision of secondary prevention services
is highly variable in Europe, with a consistent east–west
divide for many interventions. Improving the availabil-
ity of lifestyle management, rates of risk factor control
and treatment adherence, and increased access to inter-
ventions, is needed across Europe.
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